BRIEF-Hoth Therapeutics Secures European Authorization In Spain

Hoth Therapeutics, Inc

Hoth Therapeutics, Inc

HOTH

0.00

May 5 (Reuters) - Hoth Therapeutics Inc HOTH.O:

  • HOTH THERAPEUTICS SECURES EUROPEAN AUTHORIZATION IN SPAIN FOR HT-001 PHASE 2A TRIAL AS INTERIM DATA SHOW STRONG EFFICACY IN CANCER PATIENTS

  • HOTH THERAPEUTICS INC - HT-001 PHASE 2A INTERIM DATA SHOW PRIMARY EFFICACY ENDPOINT ACHIEVED BY WEEK 6

  • HOTH THERAPEUTICS INC - OVER 65% OF PATIENTS REPORTED MEANINGFUL REDUCTIONS IN PAIN AND ITCHING IN HT-001 TRIAL

  • HOTH THERAPEUTICS INC - NO PATIENTS REQUIRED DOSE REDUCTION OR DISCONTINUATION OF EGFR INHIBITOR THERAPY

  • HOTH THERAPEUTICS INC - NO TREATMENT-LIMITING ADVERSE EVENTS OBSERVED IN HT-001 PHASE 2A TRIAL

Source text: ID:nPn76tRXka

Further company coverage: HOTH.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.